The estimated Net Worth of Nell Beattie is at least $4.77 millier dollars as of 3 December 2021. Ms. Beattie owns over 8,200 units of VBI Vaccines stock worth over $4,774 and over the last 8 years she sold VBIV stock worth over $0. In addition, she makes $0 as Chief Business Officer at VBI Vaccines.
Nell has made over 4 trades of the VBI Vaccines stock since 2018, according to the Form 4 filled with the SEC. Most recently she bought 8,200 units of VBIV stock worth $20,090 on 3 December 2021.
The largest trade she's ever made was buying 10,000 units of VBI Vaccines stock on 1 October 2019 worth over $4,800. On average, Nell trades about 1,763 units every 76 days since 2017. As of 3 December 2021 she still owns at least 68,200 units of VBI Vaccines stock.
You can see the complete history of Ms. Beattie stock trades at the bottom of the page.
Nell Beattie serves as Chief Business Officer of the Company. Ms. Beattie has served as our Chief Business Officer since September 2017 and prior to that as Director, Corporate Development and Investor Relations since June 2015. She joined the Company after completing her M.B.A at the Tuck School of Business at Dartmouth College. Prior to receiving her M.B.A., she was a consultant at Artisan Healthcare Consulting, where she worked with pharmaceutical and biotechnology companies to develop financial and strategic analyses to support corporate and business development efforts, pre-launch and commercialization planning, and portfolio prioritization initiatives. Ms. Beattie also holds a B.A. from Dartmouth College.
Nell Beattie is 32, she's been the Chief Business Officer of VBI Vaccines since 2017. There are 19 older and no younger executives at VBI Vaccines. The oldest executive at VBI Vaccines Inc. is Michel Wilde, 70, who is the Independent Director.
Nell's mailing address filed with the SEC is C/O VBI VACCINES INC.,, 160 SECOND STREET, FLOOR 3, CAMBRIDGE, MA, 02142.
Over the last 8 years, insiders at VBI Vaccines have traded over $18,633,012 worth of VBI Vaccines stock and bought 55,142,222 units worth $66,770,591 . The most active insiders traders include Advisors Llcperceptive Life..., Tomer Kariv et Steven D Rubin. On average, VBI Vaccines executives and independent directors trade stock every 62 days with the average trade being worth of $130,457. The most recent stock trade was executed by Steven Gillis on 10 July 2023, trading 609,090 units of VBIV stock currently worth $1,004,999.
vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.
VBI Vaccines executives and other stock owners filed with the SEC include: